Gilead HIV Prevention Drug Advances; Novo Eyes China

Gilead Sciences ($GILD) announced the FDA accepted its supplemental New Drug Application for Yeztugo (lenacapavir) 300-mg tablet as a potential once-weekly oral formulation for HIV prevention as pre-exposure prophylaxis. The FDA assigned a PDUFA action date of February 2, 2027, positioning lenacapavir as potentially the first long-acting pill for HIV prevention. $GILD closed at $124.3, down 1.03% despite the regulatory milestone. Earlier in May, the company received FDA approval for Hepcludex for treatment of a rare and potentially fatal liver infection, reinforcing its presence in liver disease care.

Novo Nordisk ($NVO) plans to apply for Chinese regulatory approval of its oral weight-loss drug, Wegovy, expanding its geographic footprint in the obesity market. $NVO stock gained 7% over the past week following U.K. approval of oral Wegovy and positive commercial updates, though the company faces competitive pressure and near-term headwinds in 2026. Eli Lilly ($LLY) continues to experience robust growth in the obesity segment, though investors are questioning the stock's high valuation. The obesity drug market remains a key battleground for both companies as oral formulations and geographic expansion accelerate.

Johnson & Johnson ($JNJ) closed at $235.66, extending a 55% surge over the past year with returns of 1.5% over seven days, 3.9% over 30 days, 13.7% year-to-date, 55.6% over one year, 56.6% over three years, and 65.6% over five years. Investors are questioning whether $JNJ remains a solid value proposition or is starting to look fully priced after the extended rally. Pfizer ($PFE) featured in multiple analyst reports as management indicated the company may return to generating high-single-digit growth, with the business potentially in better shape than investors currently recognize. Bristol Myers Squibb ($BMY) offers a 4.39% dividend yield backed by 94 consecutive years of dividend payments as the company rebuilds around its Growth Portfolio including Eliquis, Camzyos, and Breyanzi while legacy drugs face generic erosion.

Intuitive Surgical ($ISRG) closed at $416.55, up 1.34% from the previous day, as options traders showed increased activity in the stock. The company placed 431 da Vinci systems in Q1 2026, though rising trade-ins and leasing growth raise questions about whether demand is structural or upgrade-driven. Investors are paying close attention to capital placement trends to determine if the surge represents sustained demand strength or an upgrade cycle peak. Globus Medical is accelerating product launches, FDA clearances, and R&D investment, reinforcing its strategy to expand spine and orthopedic workflows through innovation.

Thermo Fisher Scientific ($TMO) received coverage initiation from Piper Sandler with a Neutral view on June 11. The company provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services across North America, Europe, Asia-Pacific, and international markets. $TMO was included among the 14 best S&P 500 stocks to buy according to analysts. The U.S. market has stayed flat over the past week while showing a 24% increase over the past year, with earnings forecasted to grow by 19% annually.

The healthcare sector faces key catalysts including Gilead's February 2, 2027 PDUFA date for once-weekly oral lenacapavir and ongoing obesity drug competition between Novo Nordisk and Eli Lilly as both expand oral formulations and geographic reach. EGFR inhibitors market is forecast to witness growth at a 7.9% CAGR driven by next-generation TKIs, ADCs, and combination strategies with immunotherapy for indications including non-small cell lung cancer, colorectal cancer, and head and neck cancer. Investors are monitoring whether Big Pharma valuations remain sustainable following extended rallies, while medical device makers face questions about whether capital equipment demand represents structural growth or upgrade cycles.